Evaluating the EBA of Meropenem With Amoxicillin/Clavulanate and Pyrazinamide or Bedaquiline in Adults With PTB

Inclusion Criteria: * Provide written, informed consent prior to all trial-related procedures including HIV testing. * Male or female, aged between 18 and 65 years, inclusive. * Body weight (in light clothing and with no shoes) between 40 and 90 kg, inclusive. * Newly diagnosed, previously untreated, rifampicin-susceptible pulmonary TB. * A chest X-ray picture which in the opinion of the Investigator is consistent with TB. * Sputum positive on microscopy for acid-fast bacilli on at least one sputum sample (at least 1+ on the IUATLD/WHO scale). * Ability to produce an adequate volume of sputum as estimated from an overnight sputum collection sample (estimated 10 ml or more). * Be of non-childbearing potential or using effective methods of birth control throughout participation in the study until Visit 19 (day 28). Non-childbearing potential: 1. Female participant/sexual partner - bilateral oophorectomy, bilateral tubal ligation and/or hysterectomy or hasbeen postmenopausal with a history of no menses for at least 12 consecutive months; or 2. Male participant/sexual partner - vasectomised or has had a bilateral orchidectomy minimally three month prior to screening; Effective birth control methods: 1. Participant - not heterosexually active or practicing sexual abstinence; or 2. Double barrier method which can include a male condom, diaphragm, cervical cap, or female condom (male and female condoms should not be used together); or 3. Barrier method combined with hormone-based contraceptives or an intra-uterine device for the female partner. Exclusion Criteria: * Evidence of clinically significant conditions or findings, other than the indication being studied, particularly epilepsy, that might compromise safety or the interpretation of trial endpoints, per discretion of the Investigator. * Poor general condition where any delay in treatment cannot be tolerated per discretion of the Investigator. * Clinically significant evidence of extrathoracic TB (miliary TB, abdominal TB, urogenital TB, osteoarthritic TB, TB meningitis), as judged by the Investigator. * Significant history of cardiovascular disease such as heart failure, a personal or family history of congenital QT prolongation, Torsade de Pointes, or QTcF interval \> 500 ms (confirmed by repeat electrocardiogram). * History of allergy to any of the trial IP/s or related substances i.e. β-lactams and penicillin, as confirmed by the clinical judgement of the Investigator. * Alcohol or drug abuse, that in the opinion of the Investigator, is sufficient to compromise the safety or cooperation of the participant. * HIV positive ONLY IF: * CD4 \< 350cells/mm3 * On ART * Having participated in other clinical studies with investigational agents within 8 weeks prior to trial start. * Female participant who is pregnant, breast-feeding, or planning to conceive a child within the anticipated period of participating in the trial. Male participant planning to conceive a child within the anticipated period of participating in the trial. * Subjects with diabetes (Type 1 or 2), or random glucose over 11.1 mmol/L. * Hypersensitivity to local anaesthesia of amide type. * Treatment received with any drug active against Mtb (including but not limited to isoniazid, ethambutol, amikacin, cycloserine, fluoroquinolones, rifabutin, rifampicin, streptomycin, kanamycin, para-aminosalicylic acid, rifapentine, pyrazinamide, thioacetazone, capreomycin, thioamides, metronidazole), or with immunosuppressive medications such as TNF-alpha inhibitors or systemic corticosteroids, within 2 weeks prior to screening. * Participants with the following toxicities at screening as defined by the enhanced CTCEA toxicity table 1. creatinine \>1.5 times upper limit of normal (ULN); 2. haemoglobin \<8.0 g/dL; 3. platelets equal to or \<50x10E9 cells/L); 4. serum potassium \<3.0 mEq/L; 5. aspartate aminotransferase (AST) ≥3.0 x ULN; 6. alanine aminotransferase (ALT) ≥3.0 x ULN; 7. APTT grade 3 8. INR grade 3 9. Total white cell count grade 3